The UK National Institute for Health and Care Excellence has recommended a targeted twice daily drug treatment that could help around 3000 women a year with advanced breast cancer in England and Wales ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, ...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s (LSE: AZN) Truqap ...

The National Institute for Health and Care Excellence has now approved capivasertib for use on the NHS - we look at who could ...

We recently published a list of Traders Heavily Sold Down These 10 Stocks on Thursday. In this article, we are going to take ...

A "huge breakthrough" in breast cancer treatment has arrived with the NHS approval of a twice-daily pill for the most common ...

The Institute of Cancer Research, London, which helped develop the drug, welcomed the move. | ITV National News ...

A clinical trial that looked into the effects of the new pill plus fulvestrant, a hormone therapy, found that the treatment ...